AnaptysBio Inc (NAS:ANAB)
$ 13.04 -0.7 (-5.09%) Market Cap: 396.79 Mil Enterprise Value: 4.47 Mil PE Ratio: 0 PB Ratio: 4.71 GF Score: 59/100

AnaptysBio Inc To virtual BTLA Agonist (ANB032) R&D Event Transcript

May 25, 2023 / 08:15PM GMT
Release Date Price: $18.64 (-1.53%)
Operator

Good day, and thank you for standing by. Welcome to the BTLA Agonist R&D event. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Dan Faga, Interim CEO of AnaptysBio.

Daniel R. Faga
AnaptysBio, Inc. - Interim President & CEO and Director

Good afternoon, and welcome to AnaptysBio's R&D event focused on ANB032, our BTLA agonist. Today's presentation contains statements about our current plans that are forward-looking.

Joining me from Anaptys are Dr. Paul Lizzul, our Chief Medical Officer; and Dr. Martin Dahl, our SVP of Research. We're going to cover a significant amount of exciting new data and information, followed by Q&A. This will include an overview of checkpoint agonists, including deeper insight into ANB032's mechanism of action targeting BTLA.

We'll present translational preclinical data supporting the rationale to pursue development of a BTLA agonist to treat atopic dermatitis. And we will also review our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot